Conquer Cancer through AI

Issue 2 | Jul 2026

Lunit

INDEX

Q1 Highlights
- Record Revenue of KRW 93.1 Billion in 2025
- Lunit Revenue Trends (2016–2025): Growth Driven by Strong Performance across Key Business Segments
- Expanded Global Commercialization Footprint
- Lunit Insight PA Expands Access to Precision Oncology Care for patients in Underserved Regions Through Pathology Partnerships
- Awarded Seoul's National Breast Cancer Screening Program
- Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program
- Expanded Clinical Evidence of AI in Breast Cancer Screening
- Lunit Insight MMG Demonstrates Strong Performance in Dense Breast Populations, and Lunit's Lung CT AI Platform Advances in Real-World Evidence
- Lunit Insight MMG Demonstrates Strong Performance in Dense Breast Populations
- Lunit's Lung CT AI Platform Advances in Real-World Evidence

Q2 Highlights
- Record Revenue of KRW 93.1 Billion in 2025
- Lunit Revenue Trends (2016–2025): Growth Driven by Strong Performance across Key Business Segments
- Expanded Global Commercialization Footprint
- Lunit Insight PA Expands Access to Precision Oncology Care for patients in Underserved Regions Through Pathology Partnerships
- Awarded Seoul's National Breast Cancer Screening Program
- Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program
- Expanded Clinical Evidence of AI in Breast Cancer Screening
- Lunit Insight MMG Demonstrates Strong Performance in Dense Breast Populations, and Lunit's Lung CT AI Platform Advances in Real-World Evidence
- Lunit Insight MMG Demonstrates Strong Performance in Dense Breast Populations
- Lunit's Lung CT AI Platform Advances in Real-World Evidence

Q3 Highlights
- Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta
- Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare
- Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program
- Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta
- Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare
- Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

Q4 Highlights
- Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta
- Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare
- Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

Q1 Highlights

Q1 Sales Performance

Record Revenue of KRW 93.1 Billion in 2025

Lunit achieved record annual revenue of KRW 93.1 billion, with Lunit Insight MMG contributing over 50% of total revenue.

(Unit: 100M) (KRW) (Thousand) **reported approximately KRW 93.1 billion in consolidated revenue for 2025, representing a 70% year-over-year growth. Overseas sales reached approximately KRW 81.0 billion, accounting for 87% of total revenue.**

Historically, when compared to the previous year, Q1 consistently ranked as the lowest revenue quarter. However, this pattern shifted in the 2025 fiscal year, with Q1 recording the highest revenue among the four quarters for the first time.

In the Everyday group, **Lunit Insight MMG (AI for breast cancer screening) saw year-over-year growth in Q1 2026 driven by the expansion of its customer base across Europe and the United States, including major hospital groups and health-tech leaders such as Ascension and Sonic Healthcare.**

In the Oncology business group, the Company completed the integration with Lunit Insight PA (AI for pathology) and launched the product in the United States in the first quarter of 2026. At the same time, the Q1 partnership with CellCarta was further expanded to include Lunit Insight PA, strengthening the Company's pathology AI offering.

Q2 Partnership

Strategic Collaboration with CellCarta to Accelerate AI-Enabled Digital Pathology for Life Sciences

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company entered into a **strategic collaboration with CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics** and expand commercial scale and global access to precision medicine for life sciences customers.

Under the agreement, CellCarta will integrate Lunit's AI-powered digital pathology solutions into its biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 MS

Awarded a Seven-Year Contract for Seoul's National Breast Cancer Screening Program

Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

(Date: 2026.1.6) The Company was selected as the primary AI provider for Seoul's National Breast Cancer Screening Program (NBCSP), a population-based screening program for women aged 40 and above, for a contract period of 7 years. This contract covers the entire official population of 10 in metropolitan, population-based screening programs, and is expected to significantly expand the Company's AI screening participation in regional screening programs across Korea.

This award marks the first official adoption of AI in metropolitan, population-based screening programs in Korea, and is expected to drive broader adoption of AI-based screening participation in regional screening programs across Korea.

Lunit Insight MMG is a deep learning-based AI solution for breast cancer screening, designed to support radiologists in interpreting mammograms and improve cancer detection accuracy. The solution has been deployed in over 1,000 hospitals and clinics across more than 30 countries, including major healthcare systems in the United States, Europe, and Asia.

Q4 Innovation

Launching a Direct Sales Structure in Japan Alongside a Partnership Strategy

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.2.26) The Company begun direct sales in Japan through Lunit Japan, the Japanese subsidiary established in 2025. Previously, sales in Japan had been driven primarily through partnerships with local distributors. The direct sales structure is expected to drive faster adoption and deeper customer engagement, while strengthening long-term growth prospects and enhancing the sustainability of the business, such as screening and diagnostic capacity.

The Company continues to collaborate with Fujifilm. In February 2026, Fujifilm commenced commercial sales of Lunit Insight MMG in Japan, marking the first phase of this collaboration, which is expected to expand to Lunit's Lung CT AI solution in the second half of 2026. Lunit Insight MMG is the first AI solution for breast cancer screening in Japan and has been adopted by over 200 hospitals and clinics.

Q4 Partnership

Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company and CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, have expanded their strategic partnership to integrate Lunit's AI-powered digital pathology solutions into CellCarta's biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

This collaboration is expected to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics and expand commercial scale and global access to precision medicine for life sciences customers.

Q4 Partnership

Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company begun **strategic collaboration with Sonic Healthcare, one of the world's leading healthcare providers, to expand access to precision oncology care through AI-powered digital pathology.** Under the agreement, Sonic Healthcare will integrate Lunit Insight PA into its clinical workflows and deploy it across its global network of laboratories, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q1 Highlights

Q1 Sales Performance

Record Revenue of KRW 93.1 Billion in 2025

Lunit achieved record annual revenue of KRW 93.1 billion, with Lunit Insight MMG contributing over 50% of total revenue.

(Unit: 100M) (KRW) (Thousand) **reported approximately KRW 93.1 billion in consolidated revenue for 2025, representing a 70% year-over-year growth. Overseas sales reached approximately KRW 81.0 billion, accounting for 87% of total revenue.**

Historically, when compared to the previous year, Q1 consistently ranked as the lowest revenue quarter. However, this pattern shifted in the 2025 fiscal year, with Q1 recording the highest revenue among the four quarters for the first time.

In the Everyday group, **Lunit Insight MMG (AI for breast cancer screening) saw year-over-year growth in Q1 2026 driven by the expansion of its customer base across Europe and the United States, including major hospital groups and health-tech leaders such as Ascension and Sonic Healthcare.**

In the Oncology business group, the Company completed the integration with Lunit Insight PA (AI for pathology) and launched the product in the United States in the first quarter of 2026. At the same time, the Q1 partnership with CellCarta was further expanded to include Lunit Insight PA, strengthening the Company's pathology AI offering.

Q2 Partnership

Strategic Collaboration with CellCarta to Accelerate AI-Enabled Digital Pathology for Life Sciences

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company **entered into a strategic collaboration with CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics** and expand commercial scale and global access to precision medicine for life sciences customers.

Under the agreement, CellCarta will integrate Lunit's AI-powered digital pathology solutions into its biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 MS

Awarded a Seven-Year Contract for Seoul's National Breast Cancer Screening Program

Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

(Date: 2026.1.6) The Company was selected as the primary AI provider for Seoul's National Breast Cancer Screening Program (NBCSP), a population-based screening program for women aged 40 and above, for a contract period of 7 years. This contract covers the entire official population of 10 in metropolitan, population-based screening programs, and is expected to significantly expand the Company's AI screening participation in regional screening programs across Korea.

This award marks the first official adoption of AI in metropolitan, population-based screening programs in Korea, and is expected to drive broader adoption of AI-based screening participation in regional screening programs across Korea.

Lunit Insight MMG is a deep learning-based AI solution for breast cancer screening, designed to support radiologists in interpreting mammograms and improve cancer detection accuracy. The solution has been deployed in over 1,000 hospitals and clinics across more than 30 countries, including major healthcare systems in the United States, Europe, and Asia.

Q4 Innovation

Launching a Direct Sales Structure in Japan Alongside a Partnership Strategy

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.2.26) The Company begun direct sales in Japan through Lunit Japan, the Japanese subsidiary established in 2025. Previously, sales in Japan had been driven primarily through partnerships with local distributors. The direct sales structure is expected to drive faster adoption and deeper customer engagement, while strengthening long-term growth prospects and enhancing the sustainability of the business, such as screening and diagnostic capacity.

The Company continues to collaborate with Fujifilm. In February 2026, Fujifilm commenced commercial sales of Lunit Insight MMG in Japan, marking the first phase of this collaboration, which is expected to expand to Lunit's Lung CT AI solution in the second half of 2026. Lunit Insight MMG is the first AI solution for breast cancer screening in Japan and has been adopted by over 200 hospitals and clinics.

Q2 Highlights

Q2 Partnership

Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company and CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, have expanded their strategic partnership to integrate Lunit's AI-powered digital pathology solutions into CellCarta's biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

This collaboration is expected to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics and expand commercial scale and global access to precision medicine for life sciences customers.

Q4 Partnership

Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company begun **strategic collaboration with Sonic Healthcare, one of the world's leading healthcare providers, to expand access to precision oncology care through AI-powered digital pathology.** Under the agreement, Sonic Healthcare will integrate Lunit Insight PA into its clinical workflows and deploy it across its global network of laboratories, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 Highlights

Q3 Sales Performance

Record Revenue of KRW 93.1 Billion in 2025

Lunit achieved record annual revenue of KRW 93.1 billion, with Lunit Insight MMG contributing over 50% of total revenue.

(Unit: 100M) (KRW) (Thousand) **reported approximately KRW 93.1 billion in consolidated revenue for 2025, representing a 70% year-over-year growth. Overseas sales reached approximately KRW 81.0 billion, accounting for 87% of total revenue.**

Historically, when compared to the previous year, Q1 consistently ranked as the lowest revenue quarter. However, this pattern shifted in the 2025 fiscal year, with Q1 recording the highest revenue among the four quarters for the first time.

In the Everyday group, **Lunit Insight MMG (AI for breast cancer screening) saw year-over-year growth in Q1 2026 driven by the expansion of its customer base across Europe and the United States, including major hospital groups and health-tech leaders such as Ascension and Sonic Healthcare.**

In the Oncology business group, the Company completed the integration with Lunit Insight PA (AI for pathology) and launched the product in the United States in the first quarter of 2026. At the same time, the Q1 partnership with CellCarta was further expanded to include Lunit Insight PA, strengthening the Company's pathology AI offering.

Q2 Partnership

Strategic Collaboration with CellCarta to Accelerate AI-Enabled Digital Pathology for Life Sciences

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company **entered into a strategic collaboration with CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics** and expand commercial scale and global access to precision medicine for life sciences customers.

Under the agreement, CellCarta will integrate Lunit's AI-powered digital pathology solutions into its biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 MS

Awarded a Seven-Year Contract for Seoul's National Breast Cancer Screening Program

Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

(Date: 2026.1.6) The Company was selected as the primary AI provider for Seoul's National Breast Cancer Screening Program (NBCSP), a population-based screening program for women aged 40 and above, for a contract period of 7 years. This contract covers the entire official population of 10 in metropolitan, population-based screening programs, and is expected to significantly expand the Company's AI screening participation in regional screening programs across Korea.

This award marks the first official adoption of AI in metropolitan, population-based screening programs in Korea, and is expected to drive broader adoption of AI-based screening participation in regional screening programs across Korea.

Lunit Insight MMG is a deep learning-based AI solution for breast cancer screening, designed to support radiologists in interpreting mammograms and improve cancer detection accuracy. The solution has been deployed in over 1,000 hospitals and clinics across more than 30 countries, including major healthcare systems in the United States, Europe, and Asia.

Q4 Innovation

Launching a Direct Sales Structure in Japan Alongside a Partnership Strategy

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.2.26) The Company begun direct sales in Japan through Lunit Japan, the Japanese subsidiary established in 2025. Previously, sales in Japan had been driven primarily through partnerships with local distributors. The direct sales structure is expected to drive faster adoption and deeper customer engagement, while strengthening long-term growth prospects and enhancing the sustainability of the business, such as screening and diagnostic capacity.

The Company continues to collaborate with Fujifilm. In February 2026, Fujifilm commenced commercial sales of Lunit Insight MMG in Japan, marking the first phase of this collaboration, which is expected to expand to Lunit's Lung CT AI solution in the second half of 2026. Lunit Insight MMG is the first AI solution for breast cancer screening in Japan and has been adopted by over 200 hospitals and clinics.

Q4 Highlights

Q4 Partnership

Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company and CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, have expanded their strategic partnership to integrate Lunit's AI-powered digital pathology solutions into CellCarta's biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

This collaboration is expected to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics and expand commercial scale and global access to precision medicine for life sciences customers.

Q4 Partnership

Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company begun **strategic collaboration with Sonic Healthcare, one of the world's leading healthcare providers, to expand access to precision oncology care through AI-powered digital pathology.** Under the agreement, Sonic Healthcare will integrate Lunit Insight PA into its clinical workflows and deploy it across its global network of laboratories, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q1 Highlights

Q1 Sales Performance

Record Revenue of KRW 93.1 Billion in 2025

Lunit achieved record annual revenue of KRW 93.1 billion, with Lunit Insight MMG contributing over 50% of total revenue.

(Unit: 100M) (KRW) (Thousand) **reported approximately KRW 93.1 billion in consolidated revenue for 2025, representing a 70% year-over-year growth. Overseas sales reached approximately KRW 81.0 billion, accounting for 87% of total revenue.**

Historically, when compared to the previous year, Q1 consistently ranked as the lowest revenue quarter. However, this pattern shifted in the 2025 fiscal year, with Q1 recording the highest revenue among the four quarters for the first time.

In the Everyday group, **Lunit Insight MMG (AI for breast cancer screening) saw year-over-year growth in Q1 2026 driven by the expansion of its customer base across Europe and the United States, including major hospital groups and health-tech leaders such as Ascension and Sonic Healthcare.**

In the Oncology business group, the Company completed the integration with Lunit Insight PA (AI for pathology) and launched the product in the United States in the first quarter of 2026. At the same time, the Q1 partnership with CellCarta was further expanded to include Lunit Insight PA, strengthening the Company's pathology AI offering.

Q2 Partnership

Strategic Collaboration with CellCarta to Accelerate AI-Enabled Digital Pathology for Life Sciences

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company **entered into a strategic collaboration with CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics** and expand commercial scale and global access to precision medicine for life sciences customers.

Under the agreement, CellCarta will integrate Lunit's AI-powered digital pathology solutions into its biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 MS

Awarded a Seven-Year Contract for Seoul's National Breast Cancer Screening Program

Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

(Date: 2026.1.6) The Company was selected as the primary AI provider for Seoul's National Breast Cancer Screening Program (NBCSP), a population-based screening program for women aged 40 and above, for a contract period of 7 years. This contract covers the entire official population of 10 in metropolitan, population-based screening programs, and is expected to significantly expand the Company's AI screening participation in regional screening programs across Korea.

This award marks the first official adoption of AI in metropolitan, population-based screening programs in Korea, and is expected to drive broader adoption of AI-based screening participation in regional screening programs across Korea.

Lunit Insight MMG is a deep learning-based AI solution for breast cancer screening, designed to support radiologists in interpreting mammograms and improve cancer detection accuracy. The solution has been deployed in over 1,000 hospitals and clinics across more than 30 countries, including major healthcare systems in the United States, Europe, and Asia.

Q4 Innovation

Launching a Direct Sales Structure in Japan Alongside a Partnership Strategy

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.2.26) The Company begun direct sales in Japan through Lunit Japan, the Japanese subsidiary established in 2025. Previously, sales in Japan had been driven primarily through partnerships with local distributors. The direct sales structure is expected to drive faster adoption and deeper customer engagement, while strengthening long-term growth prospects and enhancing the sustainability of the business, such as screening and diagnostic capacity.

The Company continues to collaborate with Fujifilm. In February 2026, Fujifilm commenced commercial sales of Lunit Insight MMG in Japan, marking the first phase of this collaboration, which is expected to expand to Lunit's Lung CT AI solution in the second half of 2026. Lunit Insight MMG is the first AI solution for breast cancer screening in Japan and has been adopted by over 200 hospitals and clinics.

Q2 Highlights

Q2 Partnership

Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company and CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, have expanded their strategic partnership to integrate Lunit's AI-powered digital pathology solutions into CellCarta's biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

This collaboration is expected to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics and expand commercial scale and global access to precision medicine for life sciences customers.

Q4 Partnership

Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company begun **strategic collaboration with Sonic Healthcare, one of the world's leading healthcare providers, to expand access to precision oncology care through AI-powered digital pathology.** Under the agreement, Sonic Healthcare will integrate Lunit Insight PA into its clinical workflows and deploy it across its global network of laboratories, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 Highlights

Q3 Sales Performance

Record Revenue of KRW 93.1 Billion in 2025

Lunit achieved record annual revenue of KRW 93.1 billion, with Lunit Insight MMG contributing over 50% of total revenue.

(Unit: 100M) (KRW) (Thousand) **reported approximately KRW 93.1 billion in consolidated revenue for 2025, representing a 70% year-over-year growth. Overseas sales reached approximately KRW 81.0 billion, accounting for 87% of total revenue.**

Historically, when compared to the previous year, Q1 consistently ranked as the lowest revenue quarter. However, this pattern shifted in the 2025 fiscal year, with Q1 recording the highest revenue among the four quarters for the first time.

In the Everyday group, **Lunit Insight MMG (AI for breast cancer screening) saw year-over-year growth in Q1 2026 driven by the expansion of its customer base across Europe and the United States, including major hospital groups and health-tech leaders such as Ascension and Sonic Healthcare.**

In the Oncology business group, the Company completed the integration with Lunit Insight PA (AI for pathology) and launched the product in the United States in the first quarter of 2026. At the same time, the Q1 partnership with CellCarta was further expanded to include Lunit Insight PA, strengthening the Company's pathology AI offering.

Q2 Partnership

Strategic Collaboration with CellCarta to Accelerate AI-Enabled Digital Pathology for Life Sciences

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company **entered into a strategic collaboration with CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics** and expand commercial scale and global access to precision medicine for life sciences customers.

Under the agreement, CellCarta will integrate Lunit's AI-powered digital pathology solutions into its biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 MS

Awarded a Seven-Year Contract for Seoul's National Breast Cancer Screening Program

Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

(Date: 2026.1.6) The Company was selected as the primary AI provider for Seoul's National Breast Cancer Screening Program (NBCSP), a population-based screening program for women aged 40 and above, for a contract period of 7 years. This contract covers the entire official population of 10 in metropolitan, population-based screening programs, and is expected to significantly expand the Company's AI screening participation in regional screening programs across Korea.

This award marks the first official adoption of AI in metropolitan, population-based screening programs in Korea, and is expected to drive broader adoption of AI-based screening participation in regional screening programs across Korea.

Lunit Insight MMG is a deep learning-based AI solution for breast cancer screening, designed to support radiologists in interpreting mammograms and improve cancer detection accuracy. The solution has been deployed in over 1,000 hospitals and clinics across more than 30 countries, including major healthcare systems in the United States, Europe, and Asia.

Q4 Innovation

Launching a Direct Sales Structure in Japan Alongside a Partnership Strategy

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.2.26) The Company begun direct sales in Japan through Lunit Japan, the Japanese subsidiary established in 2025. Previously, sales in Japan had been driven primarily through partnerships with local distributors. The direct sales structure is expected to drive faster adoption and deeper customer engagement, while strengthening long-term growth prospects and enhancing the sustainability of the business, such as screening and diagnostic capacity.

The Company continues to collaborate with Fujifilm. In February 2026, Fujifilm commenced commercial sales of Lunit Insight MMG in Japan, marking the first phase of this collaboration, which is expected to expand to Lunit's Lung CT AI solution in the second half of 2026. Lunit Insight MMG is the first AI solution for breast cancer screening in Japan and has been adopted by over 200 hospitals and clinics.

Q4 Highlights

Q4 Partnership

Lunit's Breast Cancer AI Platform Expands Global Access to Precision Care through Strategic Collaboration with CellCarta

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company and CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, have expanded their strategic partnership to integrate Lunit's AI-powered digital pathology solutions into CellCarta's biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

This collaboration is expected to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics and expand commercial scale and global access to precision medicine for life sciences customers.

Q4 Partnership

Lunit Insight PA Expands Global Access to Precision Oncology Care through Strategic Partnership with Sonic Healthcare

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company begun **strategic collaboration with Sonic Healthcare, one of the world's leading healthcare providers, to expand access to precision oncology care through AI-powered digital pathology.** Under the agreement, Sonic Healthcare will integrate Lunit Insight PA into its clinical workflows and deploy it across its global network of laboratories, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q1 Highlights

Q1 Sales Performance

Record Revenue of KRW 93.1 Billion in 2025

Lunit achieved record annual revenue of KRW 93.1 billion, with Lunit Insight MMG contributing over 50% of total revenue.

(Unit: 100M) (KRW) (Thousand) **reported approximately KRW 93.1 billion in consolidated revenue for 2025, representing a 70% year-over-year growth. Overseas sales reached approximately KRW 81.0 billion, accounting for 87% of total revenue.**

Historically, when compared to the previous year, Q1 consistently ranked as the lowest revenue quarter. However, this pattern shifted in the 2025 fiscal year, with Q1 recording the highest revenue among the four quarters for the first time.

In the Everyday group, **Lunit Insight MMG (AI for breast cancer screening) saw year-over-year growth in Q1 2026 driven by the expansion of its customer base across Europe and the United States, including major hospital groups and health-tech leaders such as Ascension and Sonic Healthcare.**

In the Oncology business group, the Company completed the integration with Lunit Insight PA (AI for pathology) and launched the product in the United States in the first quarter of 2026. At the same time, the Q1 partnership with CellCarta was further expanded to include Lunit Insight PA, strengthening the Company's pathology AI offering.

Q2 Partnership

Strategic Collaboration with CellCarta to Accelerate AI-Enabled Digital Pathology for Life Sciences

Strengthening Commercial Scale and Global Access to Precision Medicine

(Date: 2026.1.6) The Company **entered into a strategic collaboration with CellCarta, a global contract research organization (CRO) specializing in biomarker services for oncology clinical trials, to accelerate the adoption of AI-enabled digital pathology and molecular diagnostics** and expand commercial scale and global access to precision medicine for life sciences customers.

Under the agreement, CellCarta will integrate Lunit's AI-powered digital pathology solutions into its biomarker services for oncology clinical trials and real-world evidence (RWE) studies, supporting the application of AI-based biomarkers across pharmacogenomic clinical trial testing and companion diagnostic (CDx) development.

Q3 MS

Awarded a Seven-Year Contract for Seoul's National Breast Cancer Screening Program

Lunit Insight MMG Selected for Seoul's National Breast Cancer Screening Program

(Date: 2026.1.6) The Company was selected as the primary AI provider for Seoul's National Breast Cancer Screening Program (NBCSP), a population-based screening program for women aged 40 and above, for a contract period of 7 years. This contract covers the entire official population of 10 in metropolitan, population-based screening programs, and is expected to significantly expand the Company's AI screening participation in regional screening programs across Korea.

This award marks the first official adoption of AI in metropolitan, population-based screening programs in Korea, and is expected to drive broader adoption of AI-based screening participation in regional screening programs across Korea.

Lunit Insight MMG is a deep learning-based AI solution for breast cancer screening, designed to support radiologists in interpreting mammograms and improve cancer detection accuracy. The solution has been deployed in over 1,000 hospitals and clinics across more than 30 countries, including major healthcare systems in the United States, Europe, and Asia.

Q4 Innovation

Launching a Direct Sales Structure in Japan Alongside a Partnership Strategy

Strengthening Commercial Scale and Global Access to Precision Medicine